These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12658319)

  • 1. Response from PHARMAC: difficult choices.
    Moodie P; Metcalfe S; McNee W
    N Z Med J; 2003 Mar; 116(1170):U361. PubMed ID: 12658319
    [No Abstract]   [Full Text] [Related]  

  • 2. The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care.
    Begg E; Sidwell A; Gardiner S; Nicholls G; Scott R
    N Z Med J; 2003 Mar; 116(1170):U360. PubMed ID: 12658318
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching statins: can we do harm?
    Thomas U
    N Z Med J; 1998 Jan; 111(1058):18. PubMed ID: 9490420
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluvastatin: what is the evidence?
    Bagg W; Braatvedt G
    N Z Med J; 1997 Aug; 110(1050):321-2. PubMed ID: 9315035
    [No Abstract]   [Full Text] [Related]  

  • 5. [Which statin is more efficient? Concepts and applications in economic evaluation].
    García-Altés A; Jovell AJ
    Aten Primaria; 2000 Sep; 26(5):333-8. PubMed ID: 11100606
    [No Abstract]   [Full Text] [Related]  

  • 6. PHARMAC measures savings elsewhere to the health sector.
    Metcalfe S; Dougherty S; Brougham M; Moodie P
    N Z Med J; 2003 Mar; 116(1170):U362. PubMed ID: 12658320
    [No Abstract]   [Full Text] [Related]  

  • 7. PHARMAC and statins--getting the best population health gains.
    Moodie P; Dougherty S; Metcalfe S
    N Z Med J; 2006 Jul; 119(1238):U2092. PubMed ID: 16868585
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluvastatin cost considerations.
    Garnett WR
    Ann Pharmacother; 1994 Sep; 28(9):1111-2. PubMed ID: 7803895
    [No Abstract]   [Full Text] [Related]  

  • 9. Healing unhealthy Hungarian hearts--at what cost?--With what benefit?
    Szucs TD
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):239-43. PubMed ID: 17019538
    [No Abstract]   [Full Text] [Related]  

  • 10. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PHARMAC and the statin debacle.
    Ellis C; White H
    N Z Med J; 2006 Jun; 119(1236):U2033. PubMed ID: 16807576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
    Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
    Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    Smith DG; McBurney CR
    Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes.
    Moisan J; Vaillancourt R; Grégoire JP; Gaudet M; Côté I; Leach A
    Am J Health Syst Pharm; 1999 Jul; 56(14):1437-41. PubMed ID: 10428452
    [No Abstract]   [Full Text] [Related]  

  • 16. PHARMAC and statins--correction is needed.
    Metcalfe S; Moodie P
    N Z Med J; 2007 Mar; 120(1250):U2453. PubMed ID: 17339908
    [No Abstract]   [Full Text] [Related]  

  • 17. Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders?
    MacKay P
    N Z Med J; 2005 May; 118(1214):U1433. PubMed ID: 15886729
    [No Abstract]   [Full Text] [Related]  

  • 18. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
    Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
    Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective use of statins to prevent coronary heart disease.
    Crouch MA
    Am Fam Physician; 2001 Jan; 63(2):309-20, 323-4. PubMed ID: 11201696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.